A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome

Laura Greiss Hess, Sarah E. Fitzpatrick, Danh V. Nguyen, Yanjun Chen, Kimberly N. Gaul, Andrea Schneider, Kerrie Lemons Chitwood, Marwa Abd Al Azaim Eldeeb, Jonathan Polussa, David R Hessl, Susan Rivera, Randi J Hagerman

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

OBJECTIVE:: Observational studies and anecdotal reports suggest that sertraline, a selective serotonin reuptake inhibitor, may improve language development in young children with fragile X syndrome (FXS). METHODS:: The authors evaluated the efficacy of 6 months of treatment with low-dose sertraline in a randomized, double-blind, placebo-controlled trial in 52 children with FXS aged 2 to 6 years. RESULTS:: Eighty-one subjects were screened for eligibility, and 57 were randomized to sertraline (27) or placebo (30). Two subjects from the sertraline arm and 3 from the placebo arm discontinued. Intent-to-treat analysis showed no difference from placebo on the primary outcomes: the Mullen Scales of Early Learning (MSEL) expressive language (EL) age equivalent and Clinical Global Impression Scale—Improvement. However, analyses of secondary measures showed significant improvements, particularly in motor and visual perceptual abilities and social participation. Sertraline was well tolerated, with no difference in side effects between sertraline and placebo groups. No serious adverse events occurred. CONCLUSION:: This randomized controlled trial of 6 months of sertraline treatment showed no primary benefit with respect to early EL development and global clinical improvement. However, in secondary exploratory analyses, there were significant improvements seen on motor and visual perceptual subtests, the cognitive T score sum on the MSEL, and on one measure of social participation on the Sensory Processing Measure—Preschool. Furthermore, post hoc analysis found significant improvement in early EL development as measured by the MSEL among children with autism spectrum disorder on sertraline. Treatment appears safe for this 6-month period in young children with FXS, but the authors do not know the long-term side effects of this treatment. These results warrant further studies of sertraline in young children with FXS using refined outcome measures as well as longer term follow-up studies to address long-term side effects of low-dose sertraline in early childhood.

Original languageEnglish (US)
JournalJournal of Developmental and Behavioral Pediatrics
DOIs
StateAccepted/In press - Aug 24 2016

Fingerprint

Sertraline
Fragile X Syndrome
Placebos
Language Development
Social Participation
Learning
Aptitude
Serotonin Uptake Inhibitors
Therapeutics
Observational Studies
Language
Randomized Controlled Trials
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Developmental and Educational Psychology
  • Psychiatry and Mental health

Cite this

A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome. / Greiss Hess, Laura; Fitzpatrick, Sarah E.; Nguyen, Danh V.; Chen, Yanjun; Gaul, Kimberly N.; Schneider, Andrea; Lemons Chitwood, Kerrie; Eldeeb, Marwa Abd Al Azaim; Polussa, Jonathan; Hessl, David R; Rivera, Susan; Hagerman, Randi J.

In: Journal of Developmental and Behavioral Pediatrics, 24.08.2016.

Research output: Contribution to journalArticle

Greiss Hess, Laura ; Fitzpatrick, Sarah E. ; Nguyen, Danh V. ; Chen, Yanjun ; Gaul, Kimberly N. ; Schneider, Andrea ; Lemons Chitwood, Kerrie ; Eldeeb, Marwa Abd Al Azaim ; Polussa, Jonathan ; Hessl, David R ; Rivera, Susan ; Hagerman, Randi J. / A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome. In: Journal of Developmental and Behavioral Pediatrics. 2016.
@article{7735985218d54d1595d70483ff50b3ed,
title = "A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome",
abstract = "OBJECTIVE:: Observational studies and anecdotal reports suggest that sertraline, a selective serotonin reuptake inhibitor, may improve language development in young children with fragile X syndrome (FXS). METHODS:: The authors evaluated the efficacy of 6 months of treatment with low-dose sertraline in a randomized, double-blind, placebo-controlled trial in 52 children with FXS aged 2 to 6 years. RESULTS:: Eighty-one subjects were screened for eligibility, and 57 were randomized to sertraline (27) or placebo (30). Two subjects from the sertraline arm and 3 from the placebo arm discontinued. Intent-to-treat analysis showed no difference from placebo on the primary outcomes: the Mullen Scales of Early Learning (MSEL) expressive language (EL) age equivalent and Clinical Global Impression Scale—Improvement. However, analyses of secondary measures showed significant improvements, particularly in motor and visual perceptual abilities and social participation. Sertraline was well tolerated, with no difference in side effects between sertraline and placebo groups. No serious adverse events occurred. CONCLUSION:: This randomized controlled trial of 6 months of sertraline treatment showed no primary benefit with respect to early EL development and global clinical improvement. However, in secondary exploratory analyses, there were significant improvements seen on motor and visual perceptual subtests, the cognitive T score sum on the MSEL, and on one measure of social participation on the Sensory Processing Measure—Preschool. Furthermore, post hoc analysis found significant improvement in early EL development as measured by the MSEL among children with autism spectrum disorder on sertraline. Treatment appears safe for this 6-month period in young children with FXS, but the authors do not know the long-term side effects of this treatment. These results warrant further studies of sertraline in young children with FXS using refined outcome measures as well as longer term follow-up studies to address long-term side effects of low-dose sertraline in early childhood.",
author = "{Greiss Hess}, Laura and Fitzpatrick, {Sarah E.} and Nguyen, {Danh V.} and Yanjun Chen and Gaul, {Kimberly N.} and Andrea Schneider and {Lemons Chitwood}, Kerrie and Eldeeb, {Marwa Abd Al Azaim} and Jonathan Polussa and Hessl, {David R} and Susan Rivera and Hagerman, {Randi J}",
year = "2016",
month = "8",
day = "24",
doi = "10.1097/DBP.0000000000000334",
language = "English (US)",
journal = "Journal of Developmental and Behavioral Pediatrics",
issn = "0196-206X",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome

AU - Greiss Hess, Laura

AU - Fitzpatrick, Sarah E.

AU - Nguyen, Danh V.

AU - Chen, Yanjun

AU - Gaul, Kimberly N.

AU - Schneider, Andrea

AU - Lemons Chitwood, Kerrie

AU - Eldeeb, Marwa Abd Al Azaim

AU - Polussa, Jonathan

AU - Hessl, David R

AU - Rivera, Susan

AU - Hagerman, Randi J

PY - 2016/8/24

Y1 - 2016/8/24

N2 - OBJECTIVE:: Observational studies and anecdotal reports suggest that sertraline, a selective serotonin reuptake inhibitor, may improve language development in young children with fragile X syndrome (FXS). METHODS:: The authors evaluated the efficacy of 6 months of treatment with low-dose sertraline in a randomized, double-blind, placebo-controlled trial in 52 children with FXS aged 2 to 6 years. RESULTS:: Eighty-one subjects were screened for eligibility, and 57 were randomized to sertraline (27) or placebo (30). Two subjects from the sertraline arm and 3 from the placebo arm discontinued. Intent-to-treat analysis showed no difference from placebo on the primary outcomes: the Mullen Scales of Early Learning (MSEL) expressive language (EL) age equivalent and Clinical Global Impression Scale—Improvement. However, analyses of secondary measures showed significant improvements, particularly in motor and visual perceptual abilities and social participation. Sertraline was well tolerated, with no difference in side effects between sertraline and placebo groups. No serious adverse events occurred. CONCLUSION:: This randomized controlled trial of 6 months of sertraline treatment showed no primary benefit with respect to early EL development and global clinical improvement. However, in secondary exploratory analyses, there were significant improvements seen on motor and visual perceptual subtests, the cognitive T score sum on the MSEL, and on one measure of social participation on the Sensory Processing Measure—Preschool. Furthermore, post hoc analysis found significant improvement in early EL development as measured by the MSEL among children with autism spectrum disorder on sertraline. Treatment appears safe for this 6-month period in young children with FXS, but the authors do not know the long-term side effects of this treatment. These results warrant further studies of sertraline in young children with FXS using refined outcome measures as well as longer term follow-up studies to address long-term side effects of low-dose sertraline in early childhood.

AB - OBJECTIVE:: Observational studies and anecdotal reports suggest that sertraline, a selective serotonin reuptake inhibitor, may improve language development in young children with fragile X syndrome (FXS). METHODS:: The authors evaluated the efficacy of 6 months of treatment with low-dose sertraline in a randomized, double-blind, placebo-controlled trial in 52 children with FXS aged 2 to 6 years. RESULTS:: Eighty-one subjects were screened for eligibility, and 57 were randomized to sertraline (27) or placebo (30). Two subjects from the sertraline arm and 3 from the placebo arm discontinued. Intent-to-treat analysis showed no difference from placebo on the primary outcomes: the Mullen Scales of Early Learning (MSEL) expressive language (EL) age equivalent and Clinical Global Impression Scale—Improvement. However, analyses of secondary measures showed significant improvements, particularly in motor and visual perceptual abilities and social participation. Sertraline was well tolerated, with no difference in side effects between sertraline and placebo groups. No serious adverse events occurred. CONCLUSION:: This randomized controlled trial of 6 months of sertraline treatment showed no primary benefit with respect to early EL development and global clinical improvement. However, in secondary exploratory analyses, there were significant improvements seen on motor and visual perceptual subtests, the cognitive T score sum on the MSEL, and on one measure of social participation on the Sensory Processing Measure—Preschool. Furthermore, post hoc analysis found significant improvement in early EL development as measured by the MSEL among children with autism spectrum disorder on sertraline. Treatment appears safe for this 6-month period in young children with FXS, but the authors do not know the long-term side effects of this treatment. These results warrant further studies of sertraline in young children with FXS using refined outcome measures as well as longer term follow-up studies to address long-term side effects of low-dose sertraline in early childhood.

UR - http://www.scopus.com/inward/record.url?scp=84983554869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983554869&partnerID=8YFLogxK

U2 - 10.1097/DBP.0000000000000334

DO - 10.1097/DBP.0000000000000334

M3 - Article

JO - Journal of Developmental and Behavioral Pediatrics

JF - Journal of Developmental and Behavioral Pediatrics

SN - 0196-206X

ER -